Efficacy and Challenges of Bortezomib for Adult Refractory TTP-A Case Report

Ryan Low and Tina Dutt
Additional contact information
Ryan Low: Department Postgraduate, Central Manchester University Hospitals NHS Foundation Trust, UK
Tina Dutt: Roald Dahl Centre for Thrombosis and Haemostasis, Royal Liverpool and Broadgreen University Hospitals, UK

Open Access Blood Research & Transfusion Journal, 2017, vol. 1, issue 3, 53-55

Abstract: Thrombotic Thrombocytopenic Purpura (TTP) is a rare but life threatening condition. Therapeutic plasma exchange (PLEX) remains the mainstay treatment - adjuvant immunosuppressant therapy with rituximab is also required in some patients despite this some patient remain refractory. Bortezomib has been suggested through case reports as an adjuvant therapy for refractory TTP. However, challenges exist regarding its use.

Keywords: Open Access Blood Research Journal; Open Access Blood Research & Transfusion Journal; juniper publishers; Open Access; Blood Research & Transfusion Journal; blood research impact factor; blood research topics; blood research paper; blood research & transfusion journa (search for similar items in EconPapers)
Date: 2017
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://juniperpublishers.com/oabtj/pdf/OABTJ.MS.ID.555563.pdf (application/pdf)
https://juniperpublishers.com/oabtj/OABTJ.MS.ID.555563.php (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:adp:joabtj:v:1:y:2017:i:3:p:53-55

DOI: 10.19080/OABTJ.2017.01.555563

Access Statistics for this article

Open Access Blood Research & Transfusion Journal is currently edited by Sophia Mathis

More articles in Open Access Blood Research & Transfusion Journal from Juniper Publishers Inc.
Bibliographic data for series maintained by Robert Thomas ().